WO2003072789A3 - Mikroorganismen als träger von nukleotidsequenzen kodierend für zellantigene zur behandlung von tumoren - Google Patents

Mikroorganismen als träger von nukleotidsequenzen kodierend für zellantigene zur behandlung von tumoren Download PDF

Info

Publication number
WO2003072789A3
WO2003072789A3 PCT/DE2003/000471 DE0300471W WO03072789A3 WO 2003072789 A3 WO2003072789 A3 WO 2003072789A3 DE 0300471 W DE0300471 W DE 0300471W WO 03072789 A3 WO03072789 A3 WO 03072789A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleotide sequence
cell
microorganisms
components
microorganism
Prior art date
Application number
PCT/DE2003/000471
Other languages
English (en)
French (fr)
Other versions
WO2003072789A2 (de
Inventor
Ulf R Rapp
Werner Goebel
Ivaylo Gentschev
Joachim Fensterle
Original Assignee
Medinnova Ges Med Innovationen
Ulf R Rapp
Werner Goebel
Ivaylo Gentschev
Joachim Fensterle
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP03704315A priority Critical patent/EP1478756A2/de
Priority to NZ535312A priority patent/NZ535312A/en
Priority to KR10-2004-7013483A priority patent/KR20040104464A/ko
Priority to BRPI0308119A priority patent/BRPI0308119A2/pt
Application filed by Medinnova Ges Med Innovationen, Ulf R Rapp, Werner Goebel, Ivaylo Gentschev, Joachim Fensterle filed Critical Medinnova Ges Med Innovationen
Priority to CA002513190A priority patent/CA2513190A1/en
Priority to YU75604A priority patent/RS75604A/sr
Priority to JP2003571470A priority patent/JP2005518795A/ja
Priority to MXPA04008287A priority patent/MXPA04008287A/es
Priority to IL16367203A priority patent/IL163672A0/xx
Priority to AU2003206664A priority patent/AU2003206664A1/en
Priority to US10/506,096 priority patent/US20060105423A1/en
Publication of WO2003072789A2 publication Critical patent/WO2003072789A2/de
Publication of WO2003072789A3 publication Critical patent/WO2003072789A3/de
Priority to HRP20040785 priority patent/HRP20040785A2/hr
Priority to NO20043926A priority patent/NO20043926L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/001149—Cell cycle regulated proteins, e.g. cyclin, CDC, CDK or INK-CCR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001162—Kinases, e.g. Raf or Src
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/42—Salmonella
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)

Abstract

Die Erfindung betrifft einen Mikroorganismus in dessen Genom folgende Komponenten eingefügt und exprimierbar sind: I) eine Nukleotidsequenz, kodierend für zumindest ein Epitop eines Antigens einer Tumorzelle ünd/oder eine Nukleotidsequenz für zumindest ein Epitop eines Antigens spezifisch für eine Gewebezelle, von welcher der Tumor stammt, II) optional, eine Nukleotidsequenz, kodierend für ein Protein, welches Zellen des Immunsystems stimuliert, IIIA) eine Nukleotidsequenz für ein Transportsystem, welches die Expression des Expressionsprodukts der Kompo­nenten I) und optional, II) auf der Außenfläche des Bak­teriums und/oder die Sekretion des Expressionsprodukts der Komponente I) und optional II) er­möglicht; und/oder IIIB) eine Nukleotidsequenz für ein Protein zur Lyse der Mikrooganismen im Cytosol von Säugerzellen und zur intrazellulären Freisetzung von Plasmiden enthalten in den lysierten Mikroorganismen, und IV) eine in dem Mikroorganismus aktivierbare, eine gewe­bezellspezifische oder eine nicht zellspezifische Aktivierungssequenz zur Expression einer oder mehrerer der Komponenten I) bis IIIB), wobei jede der Koponenten I) bis IV) einfach oder mehrfach eigerichtet sein kann sowie Verwendungen eines solchen Mikroorganismus zur Herstellung eines Arzneimittels.
PCT/DE2003/000471 2002-02-28 2003-02-13 Mikroorganismen als träger von nukleotidsequenzen kodierend für zellantigene zur behandlung von tumoren WO2003072789A2 (de)

Priority Applications (13)

Application Number Priority Date Filing Date Title
YU75604A RS75604A (en) 2002-02-28 2003-02-13 Microorganismus as carriers of nucleotide sequences coding for cell antigens used for the treatment of tumors
KR10-2004-7013483A KR20040104464A (ko) 2002-02-28 2003-02-13 종양을 치료하기 위해 사용되는 세포 항원을 코딩하는뉴클레오티드 서열의 캐리어로서 기능하는 미생물
BRPI0308119A BRPI0308119A2 (pt) 2002-02-28 2003-02-13 microorganismo como portadores de seqüências de nucleotídeos codificando para antígenos de células para o tratamento de tumores.
MXPA04008287A MXPA04008287A (es) 2002-02-28 2003-02-13 Microorganismos como portadores de secuencias de nucleotidos que codifican para antigenos celulares utilizados para el tratamiento de tumores.
CA002513190A CA2513190A1 (en) 2002-02-28 2003-02-13 Microorganisms as carriers of nucleotide sequences coding for cell antigens used for the treatment of tumors
NZ535312A NZ535312A (en) 2002-02-28 2003-02-13 Bacteria as carriers of nucleotide sequences coding for cell antigens used for the treatment of tumors
JP2003571470A JP2005518795A (ja) 2002-02-28 2003-02-13 癌治療のための細胞抗原をコードするヌクレオチド配列の担体としての微生物
EP03704315A EP1478756A2 (de) 2002-02-28 2003-02-13 Mikroorganismen als träger von nukleotidsequenzen kodierend für zellantigene zur behandlung von tumoren
IL16367203A IL163672A0 (en) 2002-02-28 2003-02-13 Microorganisms as carriers of nucleotide sequencescoding for cell antigens used for the treatment o f tumors
AU2003206664A AU2003206664A1 (en) 2002-02-28 2003-02-13 Microorganisms as carriers of nucleotide sequences coding for cell antigens used for the treatment of tumors
US10/506,096 US20060105423A1 (en) 2002-02-28 2003-02-13 Microorganisms as carriers of nucleotide sequences coding for cell antigens used for the treatment of tumors
HRP20040785 HRP20040785A2 (en) 2002-02-28 2004-08-27 Microorganisms as carriers of nucleotide sequences coding for cell antigens used for the treatment of tumors
NO20043926A NO20043926L (no) 2002-02-28 2004-09-20 Mikroorganismer som baerere av nukleotidsekvenser kodede for celleantigener anvendt ved behandling av tumorer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10208653.2 2002-02-28
DE10208653A DE10208653A1 (de) 2002-02-28 2002-02-28 Mikroorganismus als Träger von Nukleotidsequenzen kodierend für Zellantigene zur Behandlung von Tumoren

Publications (2)

Publication Number Publication Date
WO2003072789A2 WO2003072789A2 (de) 2003-09-04
WO2003072789A3 true WO2003072789A3 (de) 2004-02-12

Family

ID=27762489

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2003/000471 WO2003072789A2 (de) 2002-02-28 2003-02-13 Mikroorganismen als träger von nukleotidsequenzen kodierend für zellantigene zur behandlung von tumoren

Country Status (19)

Country Link
US (1) US20060105423A1 (de)
EP (1) EP1478756A2 (de)
JP (1) JP2005518795A (de)
KR (1) KR20040104464A (de)
CN (1) CN1650014A (de)
AU (1) AU2003206664A1 (de)
BR (1) BRPI0308119A2 (de)
CA (1) CA2513190A1 (de)
DE (1) DE10208653A1 (de)
HR (1) HRP20040785A2 (de)
IL (1) IL163672A0 (de)
MX (1) MXPA04008287A (de)
NO (1) NO20043926L (de)
NZ (1) NZ535312A (de)
PL (1) PL372370A1 (de)
RS (1) RS75604A (de)
RU (1) RU2319741C2 (de)
WO (1) WO2003072789A2 (de)
ZA (1) ZA200407528B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8221739B2 (en) 2004-04-29 2012-07-17 Botanic Oil Innovations, Inc. Method of cancer treatment
RU2420569C2 (ru) 2005-11-29 2011-06-10 Актогеникс Нв Индукция толерантности к антигенам через слизистую
KR100818144B1 (ko) * 2006-02-15 2008-03-31 고려대학교 산학협력단 인터페론감마를 발현하는 살모넬라 균주 및 이를 함유하는항암 치료용 조성물
US20100129406A1 (en) * 2006-09-01 2010-05-27 Anza Therapeutics, Inc. Holin-enhanced vaccines and reagents, and methods of use thereof
EP1921149A1 (de) 2006-11-13 2008-05-14 AEterna Zentaris GmbH Mikroorganismen als Träger von Nukleotidsequenzen, die für Antigene und Toxine kodieren, Verfahren zur Herstellung und deren Verwendungen
BRPI0807857A2 (pt) 2007-01-25 2014-05-27 Actogenix Nv Tratamento de doença imune por meio de distribuição através da mucosa de antígenos.
KR101104077B1 (ko) 2008-10-14 2012-01-11 건국대학교 산학협력단 Ｅｇｒ－１의 발현을 증가시키는 활성을 갖는 신규한 엔터로박테리아속에 속하는 신규균주 및 그 균주를 포함하는 조성물의 항암제로서의 용도
KR101346620B1 (ko) * 2011-11-30 2014-01-06 전남대학교산학협력단 신규 박테리아 용해 단백질 및 그의 용도
RU2551238C9 (ru) * 2013-08-02 2016-04-10 Федеральное государственное бюджетное учреждение "Медико-генетический научный центр" Российской академии медицинских наук Способ индукции апоптоза клеток злокачественной опухоли колоректального рака и средство для его осуществления
WO2018106754A1 (en) 2016-12-07 2018-06-14 Md Biosciences, Inc. Methods of synergistic treatment of cancer
WO2019155415A1 (en) * 2018-02-09 2019-08-15 Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Conicet) Immunomodulating and immunostimulating polypeptides for drug-delivery
WO2020232389A1 (en) * 2019-05-16 2020-11-19 City Of Hope Compositions and methods for targeting tumor-associated extracellular matrix components to improve drug delivery

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5156841A (en) * 1988-08-26 1992-10-20 United States Of America Anti-tumor vaccine
ZA941645B (en) * 1994-03-09 1995-01-13 South To South Co Operation In Antibodies specifically reactive against human prostate specific antigen.
WO1996014087A1 (en) * 1994-11-08 1996-05-17 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
WO2002083890A2 (en) * 2000-11-22 2002-10-24 University Of Maryland, Baltimore Use of clya hemolysin for excretion of fusion proteins

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5156841A (en) * 1988-08-26 1992-10-20 United States Of America Anti-tumor vaccine
ZA941645B (en) * 1994-03-09 1995-01-13 South To South Co Operation In Antibodies specifically reactive against human prostate specific antigen.
WO1996014087A1 (en) * 1994-11-08 1996-05-17 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
WO2002083890A2 (en) * 2000-11-22 2002-10-24 University Of Maryland, Baltimore Use of clya hemolysin for excretion of fusion proteins

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
GENTSCHEV IVAYLO ET AL: "Delivery of protein antigens and DNA by attenuated intracellular bacteria.", IJMM INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY, vol. 291, no. 6-7, February 2002 (2002-02-01), pages 577 - 582, XP009013315, ISSN: 1438-4221 *
GENTSCHEV IVAYLO ET AL: "The E. coli alpha-hemolysin secretion system and its use in vaccine development.", TRENDS IN MICROBIOLOGY, vol. 10, no. 1, January 2002 (2002-01-01), January, 2002, pages 39 - 45, XP002247589, ISSN: 0966-842X *
HAHN H P ET AL: "A Salmonella typhimurium strain genetically engineered to secrete effectively a bioactive human interleukin (hIL)-6 via the Escherichia coli hemolysin secretion apparatus", FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, ELSEVIER SCIENCE B.V., AMSTERDAM, NL, vol. 20, no. 2, February 1998 (1998-02-01), pages 111 - 119, XP002238543, ISSN: 0928-8244 *
NIETHAMMER A G ET AL: "An oral DNA vaccine against human carcinoembryonic antigen (CEA) prevents growth and dissemination of Lewis lung carcinoma in CEA transgenic mice", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 20, no. 3-4, 12 November 2001 (2001-11-12), pages 421 - 429, XP004310148, ISSN: 0264-410X *
XIANG R ET AL: "A dual-function DNA vaccine encoding carcinoembryonic antigen and CD40 ligand trimer induces T cell-mediated protective immunity against colon cancer in carcinoembryonic antigen-transgenic mice.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD.: 1950) UNITED STATES 15 OCT 2001, vol. 167, no. 8, 15 October 2001 (2001-10-15), pages 4560 - 4565, XP002247590, ISSN: 0022-1767 *
XIANG R ET AL: "An autologous oral DNA vaccine protects against murine melanoma", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 97, no. 10, 9 May 2000 (2000-05-09), pages 5492 - 5497, XP002963882, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
JP2005518795A (ja) 2005-06-30
US20060105423A1 (en) 2006-05-18
ZA200407528B (en) 2006-06-28
RU2004128929A (ru) 2005-04-10
AU2003206664A1 (en) 2003-09-09
HRP20040785A2 (en) 2004-12-31
RU2319741C2 (ru) 2008-03-20
WO2003072789A2 (de) 2003-09-04
MXPA04008287A (es) 2006-04-27
NO20043926L (no) 2004-09-20
CN1650014A (zh) 2005-08-03
KR20040104464A (ko) 2004-12-10
RS75604A (en) 2006-12-15
CA2513190A1 (en) 2003-09-04
PL372370A1 (en) 2005-07-25
NZ535312A (en) 2008-03-28
EP1478756A2 (de) 2004-11-24
IL163672A0 (en) 2005-12-18
DE10208653A1 (de) 2003-09-18
BRPI0308119A2 (pt) 2016-06-28

Similar Documents

Publication Publication Date Title
MX2009005038A (es) Microorganismos como portadores de secuencias nucleotidicas que codifican para antigeno y toxinas proteinicas, procedimiento para elaboracion y usos de los mismos.
WO2006045110A3 (en) High cell density process for growth of listeria
WO2003072789A3 (de) Mikroorganismen als träger von nukleotidsequenzen kodierend für zellantigene zur behandlung von tumoren
AU2003244855A1 (en) Method to enhance an immune response of nucleic acid vaccination
WO2003059381A3 (en) Immunogenic preparations and vaccines on the basis of mrna
WO2002061113A3 (en) Nucleic acid derived vaccine that encodes an antigen linked to a polypeptide that promotes antigen presentation
ATE286130T1 (de) Lactobacilli, die aggregations und mucin bindende gene als traeger von vakzinen enthalten
EP0752874A4 (de) Ein verstärkter, durch viren vermittelter dna-transfer
HK1086750A1 (en) Pharmaceutical composition for inducing an immune response in a human or animal
DE69806408D1 (de) Rekombinante impfstoffe die immunogene attenuierte rpos-positiv phentotyp bakterien enthalten
Grekova et al. Interferon γ improves the vaccination potential of oncolytic parvovirus H-1PV for the treatment of peritoneal carcinomatosis in pancreatic cancer
EP0873049A4 (de)
MXPA05006350A (es) Composicion de medio de cultivo, procedimiento de cultivo y mioblastos obtenidos y sus utilizaciones.
ATE374251T1 (de) Zusammensetzungen zur gentherapie von diabetes
DE69928556D1 (de) Immunmodulation mittels genetischer modifikation von dendritischen zellen und b-zellen
WO2020070678A3 (en) Antibodies specific for human and cynomolgus apoc3 and methods of use thereof
CN103160530A (zh) 一种融合基因及其应用
AR112892A1 (es) Cepa de bacillus amyloliquefaciens y método para preparar productos de soja fermentada usando el mismo
WO2002014468A3 (en) Phage-dependent superproduction of biologically active protein and peptides
WO2002051994A8 (en) Polypeptides
WO2004018630A3 (en) Recombinant double-stranded rna phages and uses thereof
CN102178950B (zh) 一种亚单位疫苗免疫佐剂及应用
AU2002212555A1 (en) Yeast derived vaccine against ipnv
WO2001025398A3 (en) Process for inducing functional tolerance to gene transfer products
HK1057233A1 (en) Hybrid cells obtainable from antigen presenting cells

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-756/04

Country of ref document: YU

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 163672

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2003571470

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/008287

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 372370

Country of ref document: PL

Ref document number: P20040785A

Country of ref document: HR

Ref document number: 1020047013483

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2003704315

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 535312

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2004/07528

Country of ref document: ZA

Ref document number: 2003206664

Country of ref document: AU

Ref document number: 200407528

Country of ref document: ZA

Ref document number: 01389/KOLNP/2004

Country of ref document: IN

Ref document number: 1389/KOLNP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2004128929

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 2003809598X

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2003704315

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020047013483

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2006105423

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10506096

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2513190

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 10506096

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2003704315

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0308119

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20040830